BioXcel Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast

Rhea-AI Summary

BioXcel Therapeutics (BTAI) announced a conference call scheduled for May 10, 2021, at 8:30 AM ET to discuss Q1 2021 financial results. The call will provide insights into the company's financial performance, particularly regarding its leading investigational drugs, BXCL501 for agitation and opioid withdrawal, and BXCL701 for aggressive prostate cancer treatment. Investors and interested parties can access the call via a domestic number or through a webcast on the company's website, with replay options available until May 24, 2021.

NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Monday, May 10, 2021 at 8:30 AM Eastern Time to discuss its first quarter 2021 operating and financial results.

Conference Call & Webcast Details
Date/Time: Monday, May 10, 2021, 8:30 AM Eastern Time
Domestic: 877-407-2985
International: 201-378-4915

The webcast will be accessible* under "Events" on the News & Media page of the Company's website at www.bioxceltherapeutics.com.

Replay
Domestic: 877-660-6853
International: 201-612-7415
Conference ID: 13719370

*Replay available through at least May 24, 2021

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com.

Contact Information:

BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.com

Investor Relations:
Mary Coleman
BioXcel Therapeutics, VP of Investment Relations
MColeman@bioxceltherapeutics.com
1.475.238.6837

John Graziano
Solebury Trout
jgraziano@soleburytrout.com
1.646.378.2942

Media:

Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com
1.646.378.2967

FAQ

What is the date of BioXcel Therapeutics' Q1 2021 conference call?

The conference call is scheduled for May 10, 2021, at 8:30 AM ET.

How can I access BioXcel Therapeutics' Q1 2021 results conference call?

You can access the call by dialing the domestic number 877-407-2985 or the international number 201-378-4915, or by watching the webcast on their website.

What are the key developments for BioXcel Therapeutics in Q1 2021?

The company will discuss its financial performance and progress on investigational drugs BXCL501 and BXCL701 during the conference call.

Is there a replay available for the BioXcel Therapeutics conference call?

Yes, a replay will be available through at least May 24, 2021.